Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach
    1.
    发明授权
    Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach 有权
    通过组合基因组学方法,生物学途径方法和顺序方法鉴定疾病的遗传基础的方法

    公开(公告)号:US09305137B1

    公开(公告)日:2016-04-05

    申请号:US12122490

    申请日:2008-05-16

    IPC分类号: G01N33/48 G06F19/00

    摘要: In one embodiment, the invention provides methods of identifying genes and genetic variants that, either alone or in combination, are important to the pathogenesis of a disease. In another embodiment, the disease is stratified by use of an immune response to disease-associated antigens. In another embodiment, the invention provides methods of identifying pathways that, either alone or in combination, are important to the pathogenesis of a disease. In another embodiment, the invention provides a method of diagnosing or predicting susceptibility to a disease in an individual by determining the presence or absence of genes and genetic variants that, either alone or in combination, are important to the pathogenesis of the disease.

    摘要翻译: 在一个实施方案中,本发明提供鉴定单独或组合地对疾病发病机制重要的基因和遗传变异体的方法。 在另一个实施方案中,通过使用对疾病相关抗原的免疫应答来分层疾病。 在另一个实施方案中,本发明提供鉴定单独或组合对疾病发病机制很重要的途径的方法。 在另一个实施方案中,本发明提供了通过确定单独或组合地对疾病的发病机制重要的基因和遗传变异体的存在或不存在来诊断或预测个体中疾病易感性的方法。

    ROLE OF IL-12, IL-23 AND IL-17 RECEPTORS IN INFLAMMATORY BOWEL DISEASE
    6.
    发明申请
    ROLE OF IL-12, IL-23 AND IL-17 RECEPTORS IN INFLAMMATORY BOWEL DISEASE 审中-公开
    IL-12,IL-23和IL-17受体在炎症性皮肤疾病中的作用

    公开(公告)号:US20100055700A1

    公开(公告)日:2010-03-04

    申请号:US12528668

    申请日:2008-02-28

    IPC分类号: C12Q1/68

    摘要: This invention provides methods of diagnosing or predicting susceptibility or protection against Inflammatory Bowel Disease in an individual by determining the presence or absence of genetic variants in the genes for IL-12, IL-23, and/or IL-17 receptors. In one embodiment, a method of the invention is practiced by determining the presence or absence of risk and/or protective haplotypes of IL-12, IL-23, and/or IL-17 receptors.

    摘要翻译: 本发明通过确定IL-12,IL-23和/或IL-17受体基因中遗传变体的存在或不存在来提供诊断或预测个体易感性或保护免疫性肠病的方法。 在一个实施方案中,通过测定IL-12,IL-23和/或IL-17受体的风险和/或保护性单倍型的存在或不存在来实施本发明的方法。

    Characterization of the CBir1 antigenic response for diagnosis and treatment of Crohn's disease
    8.
    发明授权
    Characterization of the CBir1 antigenic response for diagnosis and treatment of Crohn's disease 有权
    用于诊断和治疗克罗恩病的CBir1抗原应答的表征

    公开(公告)号:US08153443B2

    公开(公告)日:2012-04-10

    申请号:US12599549

    申请日:2008-05-09

    摘要: This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation.

    摘要翻译: 本发明通过确定遗传变异体的存在或不存在来提供诊断或预测克罗恩病敏感性的方法。 在一个实施方案中,本发明提供了通过确定抗Cbir1反应性的存在或不存在以及是否存在TLR5风险变体来诊断和/或预测个体中克罗恩病易感性的方法。 在另一个实施方案中,本发明通过确定NFκB1单倍型H3和/或ASCA表达的存在或不存在来提供诊断克罗恩病的方法。 在另一个实施方案中,本发明通过确定Cbir1特异性外周血T细胞增殖的存在或不存在来提供诊断克罗恩病的方法。

    CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE
    9.
    发明申请
    CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE 有权
    CBIR1抗原反应诊断和治疗高血糖病的特征

    公开(公告)号:US20100284999A1

    公开(公告)日:2010-11-11

    申请号:US12599549

    申请日:2008-05-09

    摘要: This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation.

    摘要翻译: 本发明通过确定遗传变异体的存在或不存在来提供诊断或预测克罗恩病敏感性的方法。 在一个实施方案中,本发明提供了通过确定抗Cbir1反应性的存在或不存在以及是否存在TLR5风险变体来诊断和/或预测个体中克罗恩病易感性的方法。 在另一个实施方案中,本发明通过确定NFκB1单倍型H3和/或ASCA表达的存在或不存在来提供诊断克罗恩病的方法。 在另一个实施方案中,本发明通过确定Cbir1特异性外周血T细胞增殖的存在或不存在来提供诊断克罗恩病的方法。